Search Grants — Free, No Account Required

Ohio Arts Council

The Ohio Arts Council Individual Excellence Awards support individual Ohio artists working in all disciplines, providing unrestricted grants to recognize and encourage the creation of new work and professional development.

Oklahoma Arts Council

The Major Grant Program provides annual operating support to established Oklahoma arts organizations with demonstrated artistic quality, community impact, and sound organizational management, strengthening the state's cultural infrastructure.

Oklahoma Arts Council

Small Grants provide flexible funding for arts activities and projects by Oklahoma nonprofit organizations, schools, and municipalities, supporting events, exhibitions, community arts programming, and arts education initiatives.

NIGMS - National Institute of General Medical Sciences

The COBRE program in this application is designed to develop the field of sensory biology on the OUHSC campus by supporting innovative research focusing on the processes used by cells to sense their environment. The COBRE will support a wide spectrum of projects using a variety of model organisms, from worms and green algae to mice and human tissue. It will support studies on cell signaling across the plasma membrane mediated by sensory organelles such as cilia and flagella; specialized signaling domains on the cell surface such as dendrites and immunological synapses; and cell surface molecules such as receptors and ion channels. It will also support research projects investigating disease and syndromes associated with sensory defects. Initially, the Oklahoma Center for Biomedical Research Excellence in Sensory Biology (OCBRESB) will take advantage of the rapidly expanding talent and expertise in cilia biology and diseases associated with defects in primary cilia on campus and then will expand to all sensory modalities. The essential biological and biomedical importance of cilia biology and the growing nexus of cilia biology researchers at OUHSC makes us uniquely positioned to develop a multidisciplinary biomedical Center of Excellence. OCBRESB will consist of an Administrative Core led by Dr. Leonidas Tsiokas, Professor and Chair of the Department of Cell Biology with research expertise on cilia biology and ion channel signaling, four Research Projects exploring mechanisms of sensory signaling in diseases affecting vision (Bennett), neurodevelopment (Craft Van de Weghe), neuronal function (Zhang), and neuropsychiatric disorders (Paterno), and two Research Cores, which will provide state-of the art support in super-resolution imaging and cell and genetic engineering. Strategically, the OCBRESB integrates perfectly well with OUHSC’s ongoing research on obesity/diabetes, vision, cancer biology; builds on the strength of Geroscience/Healthy Brain Aging; and functions as the springboard for new research activities in Neuroscience. Critically, it supports cutting-edge infrastructure needed for basic science research, traditionally the engine for discovery at OUHSC, to excel and achieve our short- and long- term strategic goals. Finally, it is essential for the development of the next generation of independent, NIH-funded talented investigators who will become leaders in an emerging area of highly relevant biomedical research. Completion of the OCBRESB will have a significant impact in enhancing biomedical research in the state of Oklahoma.

Oklahoma City Community Foundation

Oklahoma City Community Foundation ($1.5B in assets) supports nonprofits in OK through grants focused on education, community development, health, arts. Awards range from $5,000 to $250,000.

Oklahoma City Community Foundation

Oklahoma City Community Foundation ($1.5B in assets) supports nonprofits in OK through grants focused on education, community development, arts, social services. Awards range from $2,500 to $200,000.

Omaha Community Foundation

Omaha Community Foundation ($1.0B in assets) supports nonprofits in NE through grants focused on education, community development, health, arts. Awards range from $5,000 to $250,000.

Omaha Community Foundation

Omaha Community Foundation ($1.5B in assets) supports nonprofits in NE through grants focused on education, community development, arts, health. Awards range from $2,500 to $200,000.

Artist Coalition for Equitable Development

On The Block Second Saturdays is a series of six monthly outdoor street markets on 11th Ave between East Pike and East Pine every second Saturday of the month from May through October 2023. Created for and by local BIPOC artists, this free, all-ages event features a marketplace of over 38 local vendors selling handmade goods, vintage, street fashion, and more along with interactive art, community activations, and over 7 hours of DJ and live performances. This project will be completed by December 29,2023.

Ontario Arts Council

OAC distributes $60M annually to artists and organizations across all disciplines including visual arts, music, literature, theatre, dance, and media arts.

NIGMS - National Institute of General Medical Sciences

ABSTRACT The development of protein-based therapeutics has ushered in a new era of precision medicine, delivering hope and healing to millions facing severe and life-threatening conditions. Unfortunately, as natural biopolymers, protein therapeutics have fundamental limitations compared to small molecule therapeutics. Specifically, most proteins found outside their native location in the body are degraded, recognized by the immune system, lose stability/function, or are naturally cleared—a fatal flaw for a therapeutic. To overcome these limitations, therapeutic proteins may be functionalized with chemical groups to obscure their identity or increase stability. In 1990, the FDA first approved the covalent attachment of the polymer polyethylene glycol (PEG) to therapeutic proteins towards this end. When done properly, PEGylation improves the pharmacokinetic half-life, provides some masking from the immune system, and reduces side effects due to lower dosage frequency. The problem is that PEG attachment can only be done with certain amino acids (e.g. lysine, N-terminus), so control is very limited. Additionally, covalently attaching a PEG molecule to a protein is complex because this chemical modification alters the interactions and positions of the amino acid side chains, disrupting protein function. This disruption commonly outweighs the benefit, such that only 3% of FDA approved therapeutic proteins are PEGylated. This work seeks to greatly expand the benefit of PEGylating protein therapeutics by combining state of the art, computationally efficient coarse-grain molecular simulations with rapid cell-free protein synthesis and site- specific functionalization. Preliminary results have demonstrated that this simulation approach can predict with significant accuracy the optimal amino acid among the hundreds in a protein to target for PEGylation. Additionally, the cell-free protein synthesis approach allows for site-specific incorporation of a uniquely functionalized unnatural amino acid at any desired position—a capability which enables site-specific optimization of PEGylation and is crucial to broad application of the method. Using a design-build-test-learn strategy, parameterization of PEG-amino acid interactions will be incorporated into the simulation for the first time, which is hypothesized to greatly increase its accuracy. This approach will be validated with two protein therapeutics which have not yet been optimally PEGylated (Onconase for Mesothelioma/Ebola Virus Disease treatment and Crisantaspase for Acute Lymphoblastic Leukemia treatment) to improve their efficacy by increasing their activity, stability and retention.

NCI - National Cancer Institute

PROJECT SUMMARY/ABSTRACT Acute myeloid leukemia (AML) is a devastating disease with only 30% 5-year overall survival. As a blood cancer, AML appears poised to benefit from the revolution in engineered cellular therapies and bispecific antibodies. However, a lack of disease-specific targets has resulted in significant toxicity and lack of efficacy at clinically tolerable doses. The tumor necrosis superfamily member CD70 has attracted attention as a possible target to overcome these limitations, given its expression on AML and lack of or >20 fold lower expression on all normal tissues. However, current anti-CD70 CAR-Ts have shown only modest efficacy in AML models. Here, my long-term goal is to develop a new therapeutic approach to overcome these hurdles. The core hypotheses of this proposal is that 1) I can use computational engineering to create a best-in-class, naturalligand based CAR-T capable of clearing even CD70-low AML blasts and leukemic stem cells, and in parallel 2) develop a multifunctional anti-CD70 T cell therapy capable of secreting multiple T-cell-engager (TCE) antibodies in the LSC niche. Success here will define new classes of cellular therapy with curative potential in AML. This work may also outline a new therapeutic strategy use across cancers, to eliminate heterogeneous tumor in the microenvironment while sparing normal cells. To achieve these objectives, I have assembled a multidisciplinary mentorship team with complementary expertise, which includes Dr. Arun Wiita (mentor), Dr. Kevin Shannon (co-mentor), and advisory members Dr. Alexander Marson, Dr. Ansuman Satpathy, and Dr. Catherine Smith. My goal is to establish myself as an academic hematologist with a laboratory-based research program dedicated to translating cutting-edge cellular engineering technologies to solve clinically relevant problems in malignant hematology. This proposal outlines a comprehensive 5-year mentored career development plan that will provide me the essential knowledge and scientific training necessary to successfully become an independently-funded investigator. The training plan includes acquiring various new skills in cutting-edge techniques including murine cancer models and single cell biology and analysis interrogating T cell:tumor cell immunology, as well as enhancing skills in bioinformatics and R programming skills. Murine (vertebrate) studies are required as it is well known in the cell therapy field that in vitro assays are not predictive of therapeutic efficacy in human patients. UCSF provides an exceptional research environment, equipped with cutting-edge technologies and a range of leaders across multiple disciplines in addition to those on my advisory panels, in relevant fields including immunology, cellular engineering, and translational leukemia research. UCSF provides state-of-art facilities and world-renowned faculty, including those at Gladstone Institute for Genomic Immunology, UCSF Cell Design Institute (focused on cell engineering), the UCSF Center for Synthetic Immunology, the Living Therapeutics Initiative, and the UCSF Helen Diller Family Comprehensive Cancer Center.

NIMH - National Institute of Mental Health

PROJECT ABSTRACT Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) and antiretroviral therapy (ART) represent a promising but underutilized class of HIV medications that can significantly benefit patients who struggle with oral medication adherence. Despite their potential, LAIs face substantial implementation barriers due to their logistical complexity compared to traditional oral medications. While high-volume LAI delivery is currently rare across U.S. HIV clinics, clinical decision support (CDS) systems offer a potential solution for efficiently scaling LAI programs. This project addresses the critical need for infrastructural support in LAI delivery by developing and evaluating a comprehensive Resource Package to accelerate the adoption of LAI-specific CDS in HIV clinics nationwide. We hypothesize that providing clinics with a standardized Resource Package will lead to more efficient workflows, improved care coordination, enhanced patient outcomes, and sustainable LAI program growth. The Resource Package will include: (1) a compendium of LAI-specific CDS tool options with implementation guidance, (2) decision-making worksheets for CDS design, (3) low-fidelity prototypes with adaptable wireframes, (4) build checklists for tool development, and (5) evaluation metrics for assessing CDS tools. Our project has three specific aims. First, we will identify promising CDS tools and processes through synthesis of practices at 10 Clinical Partner Sites currently delivering LAIs at high volume. Second, we will co-create the Resource Package through five multi-disciplinary working groups, each including clinicians, CDS end-users, builders, and implementation scientists. Third, we will assess the Resource Package's impact on clinics' readiness to build LAI CDS tools and their progress in the build process through pre-post surveys and in-depth qualitative analysis. The project will be carried out by an interdisciplinary team including implementation scientists, clinicians, and CDS specialists, working collaboratively with 10 Clinical Partner Sites, two national dissemination partners, and a Community Advisory Board. This research directly responds to NIMH priorities (PAR-22-060 and NOT-MH-23-275) by developing a systematic intervention to promote organizational readiness and capacity for implementing LAIs with fidelity and effectiveness. By establishing a standardized approach to CDS development for LAIs, this project aims to overcome a significant barrier to widespread LAI implementation, ultimately expanding access to these valuable HIV prevention and treatment options for vulnerable populations currently underserved by conventional oral medication approaches.

NIGMS - National Institute of General Medical Sciences

Project Summary/Abstract This application requests funds to acquire the Striatech OptoDrum system, a state-of-the-art instrument for non-invasively measuring visual acuity and contrast sensitivity in mice through optomotor tracking. The OptoDrum system uses automated, head-free motion tracking to accurately quantify visual function in real-time, minimizing operator bias and animal stress. This instrumentation will directly support our NIH-funded research (R16GM149428) that examines mitochondrial-targeted neuroprotection in retinal ganglion cells following optic nerve injury. Access to the OptoDrum will significantly enhance our ability to link structural and molecular outcomes to behavioral visual function, a critical aspect currently lacking at our institution. Furthermore, this acquisition will greatly strengthen York College’s biomedical research capacity and education by providing hands-on training opportunities in neuroscience and visual physiology for undergraduate students. The OptoDrum will also enable collaborative research projects across the broader CUNY system, fostering multidisciplinary initiatives and expanding research programs. Ultimately, integrating this advanced technology into our existing research infrastructure aligns with York College's long-term goal of increasing translational neuroscience research and promoting biomedical science education.

NIDA - National Institute on Drug Abuse

Project Summary Oral nicotine pouches (ONPs)- small and dissolvable microfiber sachets pre-filled with microcrystalline powder, nicotine, and other constituents - are gaining popularity among U.S. adolescents and young adults (AYAs). In 2023, ONP was the second most used tobacco product among U.S. youth, with adolescent use rising sharply between 2023 and 2024. Among young adults, past-month ONP use doubled from 1.6% in 2022 to 3.2% in 2023. Meanwhile, monthly sales of ONP units more than tripled from 327 million in July 2021 to 1046 million in May 2024. ONPs often contain high levels of nicotine, a variety of flavors (e.g., mint, fruit), and can be used discreetly without spitting, therefore appealing to young people. Given these trends—mirroring earlier e-cigarette growth— ONP use among AYAs is expected to rise substantially in the upcoming years. In January 2025, the FDA authorized marketing for 20 Zyn nicotine pouch products with varying flavors and nicotine strengths. However, the FDA’s review primarily emphasized adult product use, and the FDA indicated that marketing authorization may be revisited based on future data on youth use. Currently, there is a dearth of evidence on risk and protective factors, longitudinal transitions, and health effects related to AYAs’ ONP use in the US population. This study will harmonize the nationally representative Population Assessment of Tobacco and Health (PATH) Study Waves 7-9 (2022-2025) Interview survey data and restricted biomarker data to examine the ONP use in adolescents (age 12-17) and young adults (18-24), including longitudinal influencing factors, transitions to other tobacco and substance use behaviors, , biomarkers of exposure (BOE) to tobacco-related toxicants, and nicotine dependence. In Aim 1, we will identify risk and protective factors associated with ONP initiation across individual, marketing exposure, social, and neighborhood domains. In Aim 2, we will apply marginal structure models to assess prospective associations of ONP use with transitions to (1) other tobacco products (e.g., cigarettes, e- cigarettes) and (2) other substances (e.g., cannabis). In Aim 3, we will examine BOE differences by ONP use status, within-subjects BOE changes in transitions, and associations between ONP use and adverse health outcomes (e.g., nicotine dependence). This study is innovative in its integration of biospecimen and survey data to model longitudinal nicotine pouch ↔ other tobacco and substance use transitions and their associated health effects. It also employs state-of-the-art statistical techniques in handling multi-domain influencing factors and time-dependent exposure and time-varying confounders. This study is significant because it provides timely evidence regarding nicotine pouch use and health outcomes in AYAs, a priority population for tobacco control policies and regulatory actions. Findings from this study are poised to inform current and future priorities for pediatric nicotine use prevention and tobacco regulatory policies on emerging ONP products. 1

OD - NIH Office of the Director

This resubmission requests funds under the NIH S10 High-End Instrumentation (HEI) Program to acquire a Thermo Scientific Orbitrap Ascend Tribrid mass spectrometer (Ascend MS), coupled with a Vanquish Neo UHPLC system, for installation in the Translational Metabolomics Shared Resource (TraM SR) Mass Spectrometry Core (MS Core) at the Medical College of Wisconsin (MCW). The MS Core will relocate to a newly constructed facility within the Center for Cancer Discovery, scheduled for completion in August 2025. To reflect the refined scope, the project title has changed from Tribrid Ascend Mass Spectrometer for Accelerating MultiOmics Research to Orbitrap Ascend Tribrid Mass Spectrometer System for Advancing Proteomics Research in Southeastern Wisconsin, emphasizing proteomics as the primary focus. The Ascend MS offers next-generation proteomics capabilities with high sensitivity, resolution, and acquisition speed. It supports ion activation methods including collision induced dissociation (CID), higher energy collisional dissociation (HCD), and electron transfer dissociation (ETD), along with ultraviolet photodissociation (UVPD), proton transfer charge reduction (PTCR), high mass range (HMRn), and the FAIMS Pro interface. These enable advanced analysis of intact proteins, post translational modifications, and low abundance targets, supporting diverse biomedical research programs. The Ascend MS will serve 19 NIH- funded investigators, including 9 Major Users with 17 active NIH awards (R01, P01, R35, T32), 9 Minor Users with 14 NIH grants (R01, R21, R35, R37, U54), and 6 Other Users including 1 with an R35. These investigators conduct high-impact research in cancer, inflammation, cardiovascular disease, infectious disease, neuroscience, pregnancy, and structural biology. The system’s ultra-low volume capabilities and advanced Orbitrap workflows will enable deep proteome profiling and high-resolution analyses, accelerating discoveries in disease mechanisms and therapeutics. The instrument will be operated and maintained by the MS Core, staffed by experienced personnel. A new full-time scientist joined on April 7, 2025, and an additional staff member will be recruited after acquisition. Operational infrastructure includes the iLab scheduling and billing platform, an advisory committee, and administrative oversight by the MCW Cancer Center’s senior business administrator. The Ascend MS will be fully utilized for fee-for-service projects, supporting NIH-funded and other researchers at MCW and partner institutions. The MCW Cancer Center has committed to subsidizing 50% of proteomics costs, ensuring affordability and broad access. The fee structure will be reviewed annually based on user surveys to maintain accessibility and responsiveness. Acquisition of the Ascend MS will transform NIH-funded research at MCW and its regional partners in southeastern Wisconsin. This state-of-the-art system will advance scientific discovery and align with the NIH mission to improve human health through cutting-edge proteomics research.

Oregon Arts Commission

Oregon Arts Commission provides grants to support arts and cultural programming, artist fellowships, arts education, and community-based arts projects across OR.

Oregon Community Foundation — Regional Programs

Oregon Community Foundation — Regional Programs ($2.5B in assets) supports nonprofits in OR through grants focused on education, environment, arts, community development. Awards range from $5,000 to $200,000.

Oregon Community Foundation

Oregon Community Foundation ($2.7B in assets) supports nonprofits in OR through grants focused on education, environment, arts, community development. Awards range from $2,500 to $200,000.

NIAMS - National Institute of Arthritis and Musculoskeletal and Skin Diseases

PROJECT SUMMARY The 2026 biennial meeting of the Orthopaedic Research Society-International Section for Fracture Repair is entitled: ORS-ISFR 19th Biennial Meeting: Advancing Bone Repair – From Basic Science to Clinical Solutions. The overall objective of this two-day meeting is to promote state-of-the-art research and scientific discourse on topics related to bone repair, with an emphasis on the ongoing need for collaboration between basic scientists, engineers and clinicians. We are committed to an interactive conference that is welcoming for trainees and early-stage investigators, with opportunities to present research, moderate sessions and network. The meeting program has been designed based on the success of past meetings, but with changes based on attendee feedback from the prior meeting. The meeting will address the most challenging problems in bone repair, with a focus on recent advances. Each session will address topics of relevance to the research priorities of the NIH. Three sessions on Day 1 will focus on basic and translational science: a) Advanced model systems and -omics in bone healing; b) Microenvironmental cues and cell metabolism in bone regeneration; and c) Innervation and angiogenesis in bone repair. Day 2 will have three clinically relevant sessions: a) Early detection of failed healing; b) Immune system and fracture – from infection to healing; c) The immune-bone axis in polytrauma and healing. There is often an information gap between what front-line clinicians treating fractures recognize as important problems, and problems that basic scientists perceive as most important. This ISFR conference aims to bridge this gap and accomplish three objectives: 1) provide a forum for clinicians to learn about the latest in basic and translational research, 2) expose basic scientists to the clinical issues that are most pressing in orthopaedic trauma, and 3) foster collaborations between researchers and clinician-scientists. Multidisciplinary approaches are essential to address challenging clinical problems. The ORS-ISFR 19th Biennial Meeting will advance understanding of fracture healing across basic, translational, and clinical perspectives.

Fugro USA Land, Inc.

Editorial and Design and Graphic and Fine Art Services

Fugro USA Land, Inc.

Editorial and Design and Graphic and Fine Art Services

NEI - National Eye Institute

Project Summary Vision is our primary sense. We rely on vision for everything from building our sense of reality, to navigating obstacles, identifying threats, and reading text and emotions. Untreatable vision loss beginning in childhood is often emotionally devastating and incurs a lifetime of healthcare expenses. This is the situation for people with Cone Dystrophy with Supernormal Rod Response (CDSRR), alternatively referred to as KCNV2 Retinopathy. In CDSRR there is a decline of vision in early childhood, followed by progressive macular degeneration by early adulthood. The hindrance to developing sight preserving treatments for CDSRR is that the etiology of macular degeneration is unknown. CDSRR is caused by mutations in a photoreceptor-specific potassium channel, Kv2.1/Kv8.2. As such CDSRR can be considered a disease of disrupted potassium homeostasis in the outer retina. Regulated potassium flux is essential for the electrical response of photoreceptors to light and can create osmotic gradients that drive water transport. Since photoreceptors have a high rate of mitochondrial respiration, generating excess metabolic wastewater that must be exported, we propose that loss of Kv2.1/Kv8.2 potassium channels in CDSRR reduces clearance of wastewater from photoreceptors, activating chronic osmotic stress signaling. In this project, we will use state-of- the-art imaging biomarkers and transcriptomics to evaluate osmotic regulation in mouse models of CDSRR.

Othello Block Party

The Othello Block Party community gathering will be held on Saturday July 28th between noon and 10:00 pm. The location for this free, family friendly event is in the cul-de-sac on 42nd Avenue South just north of South Othello Street. The goal is to highlight and celebrate the vibrant music, visual arts, culture, and activism that defines South Seattle.